SCHEMBL8749241

SCHEMBL8749241

COC(=O)C(C)Oc1cccc(O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.51
ESR1 P03372 1/20 0.46
ESR2 Q92731 1/20 0.46
TSHR P16473 3/20 0.46
ALDH2 P05091 1/20 0.46
ALDH1A1 P00352 1/20 0.46
OGG1 O15527 1/20 0.45
CHRNB4 P30926 2/20 0.44
CHRNA3 P32297 2/20 0.44
KLK7 P49862 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
F9 P00740 1/20 0.42
PLAU P00749 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10421096 0.88 STS (0.52) ESR1ESR2MEN1KMT2AMAPT
SCHEMBL1454525 0.83 L3MBTL1 (0.57) CYP3A4TSHRALDH2ALDH1A1CHRNB4
SCHEMBL13070034 0.83 CYP3A4 (0.49) CYP3A4ESR1ESR2TSHRALDH1A1
SCHEMBL27566569 0.83 ABL1 (0.53) ESR1TSHRKLK7MEN1KMT2A
SCHEMBL14121601 0.83 TP53 (0.52) CYP3A4TSHRALDH2ALDH1A1OGG1
SCHEMBL14121604 0.83 TP53 (0.52) CYP3A4TSHRALDH2ALDH1A1OGG1
SCHEMBL14122295 0.83 TP53 (0.52) CYP3A4TSHRALDH2ALDH1A1OGG1
SCHEMBL10421809 0.82 CLK1 (0.50) ALDH1A1MEN1KMT2AMAPTHPGD
SCHEMBL9559199 0.82 CYP1A2 (0.56) CYP3A4ESR1ESR2TSHRALDH1A1
SCHEMBL839599 0.82 CYP1A2 (0.55) TSHRALDH1A1KLK7MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378205-B2 Process for the preparation of triazine intermediates and a process for the preparation of UV absorbers thereof BASF SE (DE) 2025-08-05 US disclosed
US-12291509-B2 Process for the preparation of UV absorbers BASF SE (DE) 2025-05-06 US disclosed
EP-3908576-B1 A PROCESS FOR THE PREPARATION OF UV ABSORBERS BASF SE (DE) 2023-03-08 EP disclosed
US-20220119357-A1 A PROCESS FOR THE PREPARATION OF TRIAZINE INTERMEDIATES AND A PROCESS FOR THE PREPARATION OF UV ABSORBERS THEREOF BASF SE (DE) 2022-04-21 US disclosed
US-20220064129-A1 A PROCESS FOR THE PREPARATION OF UV ABSORBERS BASF CHEMICALS INDIA PVT. LTD. (IN) 2022-03-03 US disclosed
EP-3908633-A1 A PROCESS FOR THE PREPARATION OF TRIAZINE INTERMEDIATES AND A PROCESS FOR THE PREPARATION OF UV ABSORBERS THEREOF BASF SE (DE) 2021-11-17 EP disclosed
EP-3908576-A1 A PROCESS FOR THE PREPARATION OF UV ABSORBERS BASF SE (DE) 2021-11-17 EP disclosed
CN-113260679-A Process for preparing triazine intermediates and process for preparing UV absorbers thereof 巴斯夫欧洲公司 2021-08-13 CN disclosed
CN-113260611-A Method for producing UV absorbers 巴斯夫欧洲公司 2021-08-13 CN disclosed
WO-2020144094-A1 A PROCESS FOR THE PREPARATION OF UV ABSORBERS BASF SE (DE) 2020-07-16 WO disclosed
US-7629372-B2 Compounds for the treatment of dyslipidemia and other lipid disorders MERCK & CO., INC. (US) 2009-12-08 US disclosed
US-7629372-B2 Compounds for the treatment of dyslipidemia and other lipid disorders MERCK & CO., INC. (US) 2009-12-08 US disclosed
US-20080039514-A1 Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders MERCK & CO., INC. (US) 2008-02-14 US disclosed
US-20080039514-A1 Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders MERCK & CO., INC. (US) 2008-02-14 US disclosed
CN-1151696-A Antibacterial agent DAIICHI SEIYAKU CO (JP) 1997-06-11 CN disclosed
EP-0768085-A1 ANTIBACTERIAL AGENT DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1997-04-16 EP disclosed
EP-0761215-A1 ANTIBACTERIAL AGENT DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1997-03-12 EP disclosed
EP-0537538-A1 Derivatives of fluorinated phenoxyphenoxycarboxylic acid as herbicides BAYER AG (DE) 1993-04-21 EP disclosed
US-4962203-A ANTIASTHMATIC, ANTIALLERGENIC, ANTIINFLAMMATORY AND CYTOPROTECTIVE AGENTS MERCK FROST CANADA, INC. (CA) 1990-10-09 US disclosed
EP-0206751-A2 2-Substituted quinolines, their preparation and use MERCK FROSST CANADA INC. (CA) 1986-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119357-A1 A PROCESS FOR THE PREPARATION OF TRIAZINE INTERMEDIATES AND A PROCESS FOR THE PREPARATION OF UV ABSORBERS THEREOF DHPS, NISCH, UNG CYP3A4 36/4885ESR1 3476/4885ESR2 3392/4885
US-12378205-B2 Process for the preparation of triazine intermediates and a process for the preparation of UV absorbers thereof DHPS, UNG, UMPS CYP3A4 28/4885ESR1 3125/4885ESR2 3273/4885
US-20080039514-A1 Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders LIPA, APOB, LCAT CYP3A4 818/4885ESR1 4422/4885ESR2 2327/4885
US-20220064129-A1 A PROCESS FOR THE PREPARATION OF UV ABSORBERS UNG, ERCC4, UROD CYP3A4 165/4885ESR1 2540/4885ESR2 2883/4885
US-12291509-B2 Process for the preparation of UV absorbers UNG, UROD, ERCC4 CYP3A4 66/4885ESR1 2594/4885ESR2 3010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.